SCHEMBL9966008

SCHEMBL9966008

CCC(C)C(=O)N[C@H](C)C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
KMT2A Q03164 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.35
GLS O94925 1/20 0.35
KDM4E B2RXH2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
USP2 O75604 1/20 0.34
FOLH1 Q04609 2/20 0.34
NAALAD2 Q9Y3Q0 2/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
TAS1R3 Q7RTX0 2/20 0.34
TAS1R1 Q7RTX1 2/20 0.34
TAS1R2 Q8TE23 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13876693 0.80 ALDH1A1 (0.42) HSD17B10CA1CA2CA7CA14
SCHEMBL10031629 0.80 ALDH1A1 (0.42) HSD17B10CA1CA2CA7CA14
SCHEMBL115663 0.80 ALDH1A1 (0.42) HSD17B10CA1CA2CA7CA14
SCHEMBL8224748 0.78 MMP1 (0.50) HSD17B10CA1CA2KMT2ATSHR
SCHEMBL9966033 0.78 MMP1 (0.50) HSD17B10CA1CA2KMT2ATSHR
SCHEMBL2733991 0.77 FOLH1 (0.36) HSD17B10CA1CA2CA7CA14
SCHEMBL14489416 0.77 CA1 (0.38) HSD17B10CA1CA2CA7CA14
SCHEMBL13531994 0.76 ACE (0.42) HSD17B10CA1CA2CA7CA14
SCHEMBL2416451 0.76 SMN1; SMN2 (0.47) FOLH1NAALAD2MMEACECPA1
SCHEMBL14350673 0.76 PAX8 (0.39) HSD17B10CA1CA2CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HSD17B10 1976/4885CA1 4877/4885CA2 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.